A survey on the use of the MATRix regimen for Central Nervous System Lymphoma in Japan

A survey on the use of the MATRix regimen for Central Nervous System Lymphoma in Japan - A survey on the use of the MATRix regimen for CNSL in Japan

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057483

Enrollment

Registered

2025-04-01

Start date

2025-05-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma or secondary central nervous system lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with PCNSL or SCNSL before March 31, 2024 2) Patients who were at least 18 years of age at the time of initiation of the MATRix regimen 3) Patients who have received at least one cycle of the MATRix regimen (HD-MTX, HD-AraC, rituximab, and standard-dose thiotepa as remission induction therapy) for PCNSL or SCNSL

Exclusion criteria

Exclusion criteria: Patients determined to be ineligible for the study by the principal investigator or sub-investigators

Design outcomes

Primary

Measure	Time frame
Incidence and frequency of adverse events and adverse reactions	—

Secondary

Measure	Time frame
1) Effectiveness of the MATRix regimen (overall response rate, progression-free survival, overall survival) 2) Treatment details of the MATRix regimen (number of cycles, dose per cycle) 3) Clinical laboratory values	—

Countries

Japan

Contacts

Public ContactMayu Kakiuchi

Mebix, Inc. Clinical Operations

matrix2022@mebix.co.jp03-4362-4500

Outcome results